Biotic Supplements in Patients With Chronic Kidney Disease: Meta-Analysis of Randomized Controlled Trials

Liu, Jing; Zhong, Jian; Yang, Haichun; Wang, DongQin; Zhang, Ying; Yang, Yumeng; Xing, Guolan

doi:10.1053/j.jrn.2021.08.005

Cited by 17 publications

(11 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to the findings of our study, meta-analysis reported by Liu, J. et al. found serum creatinine decreased after biotic supplementation in dialysis patients [ 36 ], possibly because which was conducted in the dialysis patients. Another recent meta-analysis [ 37 ] also reported that probiotics decreased serum creatinine in diabetic kidney disease, probably because this meta-analysis included only studies of diabetic nephropathy and did not exclude dialysis patients.…”

Section: Discussioncontrasting

confidence: 99%

Effects of prebiotics, probiotics and synbiotics on serum creatinine in non-dialysis patients: a meta-analysis of randomized controlled trials

Liu

et al. 2023

Renal Failure

View full text Add to dashboard Cite

Objective Serum creatinine level are influenced by many factors. Although accumulated data suggested that prebiotics, probiotics and synbiotics supplements could affect serum creatinine level, the results remained controversial. The aim of the present paper was to evaluate the effects of prebiotics, probiotics and synbiotics on serum creatinine in non-dialysis patients. Methods PubMed, EMBASE (Excerpta Medica Database) and the Cochrane Library databases were searched for eligible randomized, controlled trials (RCTs) which were limited to English language studies until 30 September 2022. A random-effects model was performed to analyze the impact of pooled trials. Result Twelve randomized, controlled trial studies were included in the meta-analysis. Prebiotics, probiotics or synbiotics supplementation did not significantly decrease the serum creatinine levels in non-dialysis patients compared to placebo [standardized mean difference (SMD) = 0.05; 95% confidence interval (CI): (−0.21, 0.31); p = 0.72; I 2 = 61%]. Conclusion The present meta-analysis indicated that supplementation with prebiotics, probiotics and synbiotics could not act as promising adjuvant therapies to decrease the serum creatinine levels in non-dialysis patients.

show abstract

Section: Discussioncontrasting

confidence: 99%

Effects of prebiotics, probiotics and synbiotics on serum creatinine in non-dialysis patients: a meta-analysis of randomized controlled trials

Liu

et al. 2023

Renal Failure

View full text Add to dashboard Cite

show abstract

“…Щорічно майже 5 % смертей пов'язані з порушенням функції нирок. На сьогодні ХХН є глобальним тягарем для охорони здоров'я, прогресування ХХН до 5-ї стадії пов'язане зі суттєвим збільшенням витрат (у 1,3-4,2 раза), і витрати на одного пацієнта на рік становлять 20 000-100 000 доларів США [1][2][3][4][5][6][7][8][9].…”

Section: якість життя хворих з додіалізною хронічною хворобою нирок ї...unclassified

“…ХХН негативно впливає на ЯЖ, збільшує тривалість стаціонарного лікування, потребує постійного спостереження в лікаря й довічного лікування. Проблема ЯЖ хворих із ХХН є актуальною.Отримані нами результати підтверджують дані багатьох досліджень (CKD-PC, INCIPE, PREVEND, CKD-ROUTE[16] та ін [9,[17][18][19][20][21]…”

unclassified

Quality of life of patients with pre-dialysis chronic kidney disease, its relationship with oxidant stress and uromodulin excretion

Denova

Ivanov

2023

KIDNEYS

View full text Add to dashboard Cite

Background. The purpose of this study was to assess the quality of life (QoL) in patients with pre-dialysis chronic kidney disease (CKD), to reveal the factors affecting the QoL in this category of patients and to investigate the effect of antioxidant therapy on the QoL of patients with CKD stages 1–5. Materials and methods. Patients with CKD (n = 61), whose average age was 44.51 ± 11.90 years, were included in the study. Twenty (32.79 %) men and 41 (67.21 %) women were divided into two groups representative in terms of age and gender composition: group 1 (n = 31) — patients with CKD who took glutathione 100 mg 2 times a day with meals for 3 months, group 2 (n = 30) — those with CKD who took ubiquinone 100 mg once daily with meals for 3 months. The QoL was assessed using the SF-36 questionnaire. Patient adherence to treatment was assessed with the Morisky-Green test. To assess the kidney function of patients, the level of urinary uromodulin excretion (uUMOD), urine albumin-to-creatinine ratio (ACR) were determined. The impact of antioxidant therapy on the QoL of these patients was evaluated and the factors affecting QoL were determined. Results. In the structure of CKD, urolithiasis was most common — 22 (36.1 %) patients, 5 (8.2 %) people had chronic pyelonephritis, 18 (29.5 %) — diabetic nephropathy, 4 (6.6 %) — polycystic kidney disease, 6 (9.8 %) — gouty nephropathy, 1 (1.6 %) — chronic glomerulonephritis and 5 (8.2 %) patients presented with hypertensive nephropathy. The duration of CKD in the first group was 5.42 ± 3.88 (1; 15) years, in the second one — 5.57 ± 3.79 (1; 16) years, no significant difference was found between the groups in terms of age and gender (U = 463m, p = 0.9827). In all patients, the indicators at the beginning were lower than those by the end of the study. The lowest indicator in the first group is general health, in the second — vitality. The psychological component of health (PsCH) was lower than the physical component of health (PhCH) in both groups. A significant positive relationship (p < 0.001) was observed, which was most pronounced for glomerular filtration rate (GFR), ACR, systolic blood pressure, hemoglobin. At the end of the study, 12 (19.67 %) patients had 4 points on the Morisky-Green test, which meant high adherence to therapy. There was a reliable strong positive relationship between the QoL and GFR, ACR, uUMOD. At the beginning of treatment, a significant average positive relationship was found between the QoL (PhCH) and uUMOD: r (59) = 0.372, p = 0.003; between the QoL (PhCH) and GFR, there is a significant positive relationship: r (59) = 0.707, p < 0.001. There is a very insignificant positive relationship between the QoL (PsCH) and patients’ adherence to treatment, r (59) = 0.0882, p = 0.499. Conclusions. Antioxidant therapy with glutathione and ubiquinone significantly improves the QoL of patients with CKD. Considering the safety and effectiveness of antioxidant therapy, we suggest including antioxidant therapy in treatment protocols for patients with CKD. Further research is recommended to determine a standard protocol.

show abstract

“…Use of probiotics may enrich the gut microbiota, enhance immune response, restore intestinal permeability, and promote anti-inflammatory effects 4 by correcting dysbiosis, thus potentially producing beneficial effects for patients with CKD 3 . Recent literature reviews on the administration of probiotics to patients with CKD reported favorable effects, observed as decreases in the levels of biomarkers of oxidative stress (malondialdehyde), inflammation (interleukin-6), urea, p-cresol, ammonia, among other positive effects 5 , 6 .…”

Section: Introductionmentioning

confidence: 99%

Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial

et al. 2023

View full text Add to dashboard Cite

Introduction: Supplementation with probiotics for patients with chronic kidney disease (CKD) may be associated with decreased systemic inflammation. Objective: To assess the impact of oral supplementation with probiotics for patients with CKD on hemodialysis. Method: This double-blind randomized clinical trial included 70 patients on hemodialysis; 32 were given oral supplementation with probiotics and 38 were in the placebo group. Blood samples were collected at the start of the study and patients were given oral supplementation with probiotics or placebo for three months. The probiotic supplement comprised four strains of encapsulated Gram-positive bacteria: Lactobacillus Plantarum A87, Lactobacillus rhamnosus, Bifidobacterium bifidum A218 and Bifidobacterium longum A101. Patients were given one capsule per day for 3 months. Blood samples were taken throughout the study to check for inflammatory biomarkers. Non-traditional biomarkers Syndecan-1, IFN-y, NGAL, and cystatin C were measured using an ELISA kit, along with biochemical parameters CRP, calcium, phosphorus, potassium, PTH, GPT, hematocrit, hemoglobin, glucose, and urea. Results: Patients given supplementation with probiotics had significant decreases in serum levels of syndecan-1 (239 ± 113 to 184 ± 106 ng/mL, p = 0.005); blood glucose levels also decreased significantly (162 ± 112 to 146 ± 74 mg/dL, p = 0.02). Conclusion: Administration of probiotics to patients with advanced CKD was associated with decreases in syndecan-1 and blood glucose levels, indicating potential improvements in metabolism and decreased systemic inflammation.

show abstract

Biotic Supplements in Patients With Chronic Kidney Disease: Meta-Analysis of Randomized Controlled Trials

Cited by 17 publications

References 77 publications

Effects of prebiotics, probiotics and synbiotics on serum creatinine in non-dialysis patients: a meta-analysis of randomized controlled trials

Effects of prebiotics, probiotics and synbiotics on serum creatinine in non-dialysis patients: a meta-analysis of randomized controlled trials

Quality of life of patients with pre-dialysis chronic kidney disease, its relationship with oxidant stress and uromodulin excretion

Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial

Contact Info

Product

Resources

About